Document is current
Any future updates will be listed below
-
Authors
Chen, Amanda X. Y.
Yap, Kah Min https://orcid.org/0000-0001-5009-9895
Kim, Joelle S. https://orcid.org/0000-0001-9213-6180
Sek, Kevin https://orcid.org/0000-0003-4634-7600
Huang, Yu-Kuan https://orcid.org/0000-0003-2262-7069
Dunbar, Phoebe A.
Wiebking, Volker https://orcid.org/0000-0002-9429-5254
Armitage, Jesse D.
Munoz, Isabelle https://orcid.org/0000-0001-6510-5696
Todd, Kirsten L. https://orcid.org/0000-0002-3903-166X
Derrick, Emily B. https://orcid.org/0000-0001-7191-3948
Nguyen, Dat
Tong, Junming https://orcid.org/0009-0006-6454-8704
Chan, Cheok Weng
Hoang, Thang X.
Audsley, Katherine M.
van Elsas, Marit J. https://orcid.org/0000-0001-9955-6356
Middelburg, Jim https://orcid.org/0000-0002-4797-9653
Lee, Joel N.
de Menezes, Maria N. https://orcid.org/0000-0003-3231-0620
Cole, Thomas J.
Li, Jasmine
Scheffler, Christina https://orcid.org/0000-0003-3731-6204
Scott, Andrew M.
Mackay, Laura K. https://orcid.org/0000-0002-8496-6632
Waithman, Jason https://orcid.org/0000-0003-4940-0155
Oliaro, Jane https://orcid.org/0000-0002-2097-6428
Harrison, Simon J. https://orcid.org/0000-0003-4555-6582
Parish, Ian A. https://orcid.org/0000-0003-3528-478X
Lai, Junyun https://orcid.org/0000-0001-5884-2786
Porteus, Matthew H. https://orcid.org/0000-0002-3850-4648
House, Imran G.
Darcy, Phillip K. https://orcid.org/0000-0002-5303-9561
Beavis, Paul A. https://orcid.org/0000-0002-2116-013X
- License Information
-
More Information
Article History
Received: 14 December 2023
Accepted: 29 May 2025
First Online: 2 July 2025
Competing interests
: P.A.B. declares research funding from Bristol-Myers-Squibb. P.K.D. declares research funding from Myeloid Therapeutics, Prescient Therapeutics, Bristol-Myers-Squibb and Juno Therapeutics. I.A.P. declares research funding from AstraZeneca, Bristol-Myers-Squibb and Roche Genentech. The authors declare the following patents related to this work: PCT/AU2021/051219, ‘Composition and methods for immunotherapy’ (19 October 2021) (A.X.Y.C., I.G.H., P.K.D. and P.A.B.); and PCT/AU2024/050379, ‘Compositions & methods for immunotherapy – II’ (20 April 2023) (A.X.Y.C., K.M.Y., P.K.D. and P.A.B). M.H.P. serves on the Scientific Advisory Board of Allogene Therapeutics and Biogen. He is on the Board of Directors and has equity in Kamau Therapeutics and has equity in CRISPR Therapeutics. The remaining authors declare no competing interests.
